INTRODUCTION
============

Pancreatitis in systemic lupus erythematosus (SLE) is a rare but serious complication. Less than 200 cases have been reported in literature with an annual incidence of 2.3/1000 SLE patients \[[@R1],[@R2]\]. We report our experience on profile and treatment outcome of SLE patients with acute pancreatitis and a comparison of these with patients presenting with abdominal pain due to causes other than pancreatitis.

PATIENTS AND METHODS
====================

Records of SLE inpatients admitted with pain abdomen between 2008 to 2010 were studied retrospectively. All patients had fulfilled ACR 1997 revised classification criteria \[[@R3]\]. Details of demography, clinical features, SLE disease activity assessment (SELENA SLEDAI), laboratory parameters, imaging studies and management were noted \[[@R4]\]. Patients were categorized into those with abdominal pain due to pancreatitis and those with pain of non pancreatic etiology. Diagnosis of acute pancreatitis was made in the presence of abdominal pain or tenderness characteristic of pancreatitis, with at least 2 fold elevation of serum pancreatic enzymes i.e. serum amylase or lipase with or without imaging features \[[@R5]\]. Those with pancreatitis were further sub-classified into mild and severe subsets using Atlanta criteria, 1992 \[[@R6]\].

Data was analyzed using SPSS-version 15. Fischer's exact test was used to compare the two groups. The p value of \<0.05 was considered statistically significant.

RESULTS
=======

Among 551 SLE patients admitted during the study period (data retrieved from our SLE database), 28 (5%) had presented with abdominal pain and 11 (2%) of them were diagnosed to have acute pancreatitis. Five of these 11 patients had severe pancreatitis and 6 had mild pancreatitis.

Causes of abdominal pain of non pancreatitis origin included mesenteric ischemia, diagnosed clinically by characteristic abdominal pain and normal pancreatic enzymes in 1, probable intestinal vasculitis in 2, blood culture proven septicemia in 1, post surgery subacute obstruction due to intestinal adhesions in 1, acute gastroenteritis in 1 and no identifiable causes in 11 patients. Pancreatitis was ruled out in these 17 patients by absence of characteristic abdominal pain and/or by lack of elevated levels of pancreatic enzymes which were measured in 8 out of these 17 patients.

Majority of patients were females (26/28) and mean age was 26.7 ± 6.7 years. The median disease duration of SLE in patients with pancreatitis was 12 (range 2 - 72) months. None of the patients with pancreatitis had history of diabetes, alcoholism and cholelithiasis. Serum calcium and triglyceride levels were measured in 8/11 and 6/11 patients with pancreatitis respectively, but none of them had hypercalcemia or triglyceride levels more than 500mg/dl. No patient with pancreatitis was on azathioprine within the preceding 3 months.

A comparison of salient clinical features and lab parameters of patients with pancreatic and non pancreatic abdominal pain is listed in Table **[1](#T1){ref-type="table"}**.

DISCUSSION
==========

Articular involvement and occurrence of generalized tonic clonic seizures were significantly more common in patients with pancreatitis. This could be explained by high SLE disease activity in these patients. Other factors contributing to higher frequency of seizures in these patients could be electrolyte imbalance, antiphospholipid antibody syndrome or renal failure. Though 40% of our SLE patients with pancreatitis tested positive for antiphospholipid antibodies i.e. Lupus anticoagulant (LA) or Anticardiolipin antibody (aCLA), this frequency was not significantly different from that in patients with abdominal pain of non pancreatic origin, similar to that reported in earlier series \[[@R7]\]. None of our patients with pancreatitis had psychosis and only one had skin rash suggestive of cutaneous vasculitis, which was less frequent than reported incidence in series by Makol *et al.,* \[[@R7]\].

Lack or withdrawal of prior steroid usage was also significantly associated with pancreatitis (7/11 *vs* 4/17, p\< 0.05) in our series. Moreover , withdrawl of low dose maintenance steroid therapy was more often seen in severe as compared to mild pancreatitis (4/6 *vs* 0/5, p= 0.061). These associations could again reflect relapse of disease activity due to suboptimal therapy. The association of high SLE disease activity with bad outcome in pancreatitis has already been reported in a previous study \[[@R8]\].

A multivariate analysis was done for independent predictors for pancreatitis, using the above three items found significant in univariate analysis and it did not reveal any significance probably due to smaller number of patients. Once pancreatitis was diagnosed, all our patients were treated with high dose steroids irrespective of severity status of pancreatitis. One patient was given anticoagulation in addition, due to moderately positive lupus anticoagulant and deep vein thrombosis.

Four patients (36%) had adverse outcome in the form of fatality in 2 and multiorgan dysfunction requiring ventilatory support in the remaining two. This figure is higher than that in other studies, which could possibly be explained by higher infection rate in our patients \[[@R2],[@R7],[@R9]\].

In summary, pancreatitis was rare (2%) in our cohort of inpatients with SLE. Seizures, arthritis and discontinuation of maintenance dose of steroids were significantly more common in patients with pancreatitis, when compared to those with abdominal pain of non pancreatic origin. Occurrence of seizure went hand in hand with severity of pancreatitis. Forty percent of SLE patients with pancreatitis had antiphospholipid antibodies, similar to that in SLE patients with other causes of abdominal pain.
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A Comparison of Salient Clinical Features and Lab Parameters of Patients

  Parameters                                        Abdominal Pain of Non Pancreatic Origin   Abdominal Pain Due to Pancreatitis
  ------------------------------------------------- ----------------------------------------- ---------------------------------------
  Cutaneous involvement                             3/17                                      6/11
  Articular involvement                             4/17                                      9/11 [\*](#T1F2){ref-type="table-fn"}
  Serositis (pleural/pericardial effusion)          3/17                                      4/11
  GTCS                                              0/17                                      6/11 [\*](#T1F2){ref-type="table-fn"}
  Psychosis                                         1/17                                      0/11
  Anemia                                            16/17                                     11/11
  Leucopenia (WBC count \< 4000/mm3)                4/17                                      3/11
  Thrombocytopenia (platelet count \< 100000/mm3)   4/17                                      2/11
  Proteinuria (24 hr urine protein \> 500mg)        11/15                                     4/10
  Elevated creatinine (\>1.4 mg/dl)                 1/11                                      5/11
  Low C3 (\< 90 mg/dl)                              11/15                                     11/11
  Low C4 (\< 10mg/dl)                               8/15                                      10/11
  Positive LA by dRVVT test                         7/8                                       4/10
  Positive aCLA (\> 12 U/ml)                        6/13                                      4/10
  Mean SLEDAI                                       15±12                                     22 ± 11

GTCS: generalized tonic clonic seizure, LA: lupus anticoagulant, ACLA : anticardiolipin antibody.

p \< 0.05.
